Recent technological advancements suggest that PET-CT with new tracers, such as ligands that bind to prostate-specific membrane antigen (PSMA), may be able to differentiate prostate cancer metastasis from osteonecrosis. The gene discussed is FOLH1; the disease is prostate carcinoma.